Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Bis(linoleyl) ketone

  Cat. No.:  DC65720   Featured
Chemical Structure
1169768-30-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86 21 58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Cas No.: 1169768-30-2
Chemical Name: 6,9,28,31-Heptatriacontatetraen-19-one, (6Z,9Z,28Z,31Z)-
Synonyms: 6,9,28,31-Heptatriacontatetraen-19-one, (6Z,9Z,28Z,31Z)-;(6Z, 9z, 28z, 31z) - 6,9,28,31-heptatriacontatetraen-19-one;(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-one
SMILES: CCCCC/C=C\C/C=C\CCCCCCCCC(=O)CCCCCCCC/C=C\C/C=C\CCCCC
Formula: C37H66O
M.Wt: 526.919352054596
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Cat. No. Product name Field of application
DC67602 ILB-3132(E12LA6B603) E12LA6B603(ILB3132,ILB-3132) is a novel ionizable amino lipid disclosed in patent WO2024198497A1, developed by MagicRNA, representing a highly efficient component for lipid nanoparticle (LNP) delivery systems.When formulated into LNPs, E12LA6B603 LNP achieves a remarkable 98.26% encapsulation efficiency for mRNA. It mediates superior in vitro transfection in dendritic cells (1.8E+05 intensity) and demonstrates best-in-class in vivo protein expression after intramuscular injection (2.2E+09 intensity). Most notably, in a B16-OVA melanoma model, therapeutic OVA-mRNA vaccines delivered by E12LA6B603 LNPs induced 100% complete tumor regression, highlighting its superior efficacy over benchmarks like DLin-MC3 and SM-102. Its biodegradable ester linkages and balanced structure make it a promising, potent candidate for next-generation mRNA vaccines and therapeutics.
DC67450 A28-C6B2 A28-C6B2 is a biodegradable ionizable lipid specifically engineered for spleen-targeted delivery. Through its unique branched structure, it bypasses hepatic uptake to achieve highly efficient transfection of F4/80+ macrophages and CD11c+ dendritic cells within the spleen. This lipid remains neutral in the bloodstream to minimize non-specific interactions, while undergoing protonation in the acidic environment of the endosome to facilitate nucleic acid release, thereby significantly enhancing the potency of mRNA vaccines and immunotherapies.
DC67096 DMG-PEG-NHS (MW2000) DMG-PEG2000-NHS is a PEG derivative that can be used in various biomedical applications, such as the construction of drug delivery systems (siRNA delivery liposomes, lipid nanoparticle, etc.). The active ester (NHS) can react with an amino group (-NH2) to form a stable amide bond, which can be used as a linker in a bioconjugation strategy to modify amino-linked peptide proteins as well as other small molecules.
DC60676 MRT6160 MRT-6160 represents a groundbreaking molecular glue degrader designed to selectively target VAV1, achieving its proteasomal degradation with a DC50 value of 7 nM. This innovative compound showcases its unique mechanism and therapeutic potential.
DC65781 DPyPE DPyPE is a phosphatidylethanolamine lipid composed of polyisoprene alkyl chains. DPyPE is a co-lipid forvaxfectin mixed with GAP-DMORIE in a 1:1 ratio.
DC65720 Bis(linoleyl) ketone
DC83220 ALC-0315 analogous-1 ALC-0315 analogous-1 is a derivative of the ionizable cationic amino lipid ALC-0315. It has been used in the synthesis of ionizable cationic lipids used in the generation of lipid nanoparticles (LNPs).
DC39053 XP-59 XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM[1].The SARS-CoV main proteinase (Mpro) plays a central role in the formation of the viral replicase/transcriptase complex and is thus an ideal target for the development of suitable dru
DC39052 LQZ-7I LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors[1].
DC39042 FGI-106 FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively[1].FGI-106 is a potent compound for COVID-19 treament.
X